The inhibition of DNA synthesis in chronic lymphocytic leukaemia cells by chlorambucil in vitro.
The inhibition of 3H-thymidine incorporation into the DNA of mitogen-stimulated lymphocytes from patients with chronic lymphocytic leukaemia by chlorambucil was measured in vitro and the results related to clinical drug resistance. The assay proved to be both sensitive and specific showing a clear separation of those patients with responsive disease from those with disease resistant to treatment. There was evidence of primary drug resistance in untreated patients. In almost all patients who received treatment this led to increasing resistance to chlorambucil in vitro. The assay is predictive of clinical responsiveness and provides a potential means whereby new therapeutic agents and treatment modifiers may be investigated.
Bentley
D P
DP
Department of Haematology, Llandough Hospital, Penarth, South Glamorgan, UK.
Blackmore
J A
JA
D002699:Chlorambucil / Q000494:pharmacology*; D004273:DNA, Neoplasm / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000378:metabolism*; D007958:Leukocyte Count / Q000187:drug effects; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D013936:Thymidine / Q000493:pharmacokinetics
D004273:DNA, Neoplasm; D002699:Chlorambucil; D013936:Thymidine